Clinical trials

The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host disease (cGVHD) that is refractory to corticosteroid treatment. The main questions it seeks to answer are: * Is MesenCell infusion safe in patients with corticosteroid-refractory chronic graft-versus-host disease? * Can MesenCell treatment improve the clinical response and disease control in these patients? Participants will receive one to three intravenous infusions of MesenCell, according to the study protocol and be followed for 12 months after the last MesenCell infusion.